Physician profile
Chadwick E Huggins
NPI 1255443461
$2,665.62
in general payments reported to CMS, 2019-2025
20 companies · $602 in 2025
The $602 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $83.93 · 2021: $177 · 2022: $391 · 2023: $444 · 2024: $809 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $532.12 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $366.15 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Novartis Pharmaceuticals Corporation | $354.61 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $329.82 | 2019-2023 | Xarelto |
| Amgen INC. | $168.86 | 2019-2025 | Repatha, Repatha |
| Atricure, INC. | $165.81 | 2024 | |
| Cvrx, INC. | $159.88 | 2023-2025 | Barostim Neo System |
| Abiomed | $140.55 | 2019-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $72.08 | 2023-2024 | Inpefa |
| Philips North America LLC | $58.71 | 2020-2023 | |
| Cardiva Medical, INC. | $56.98 | 2024 | Optowire, Savvywire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.56 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $43.95 | 2022-2024 | Watchman Flx |
| Pfizer INC. | $37.48 | 2020-2024 | |
| Baxter Healthcare | $33.94 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.27 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $18.50 | 2019 | |
| Merck Sharp & Dohme LLC | $16.24 | 2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $15.67 | 2025 | |
| Medtronic Vascular, INC. | $14.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadwick Huggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.